Cancer Home > Eribulin Medication Information

If you have breast cancer, your healthcare provider may prescribe eribulin mesylate (HalavenTM). This prescription drug is specifically designed for people who have late-stage breast cancer that has not adequately responded to certain other chemotherapy treatments.
Eribulin is administered intravenously (through an IV) and is given on day 1 and day 8 of a 21-day cycle. Fatigue, nerve problems, and low levels of certain white blood cells are some of the possible side effects of this drug.
It's important to review eribulin's safety information with your healthcare provider before starting treatment. This medication may not be suitable for everyone, so make sure your healthcare provider is aware if you have any other medical conditions (such as kidney disease, liver disease, or low blood counts) or if you are taking any other types of medicine (including nonprescription products and herbal supplements).
(For more information on this chemotherapy medication, click Eribulin. This article provides a more in-depth discussion, explaining how eribulin works, what to expect when receiving it, and how to ensure the effectiveness of each dose.)
Written by/reviewed by:
Last reviewed by: Arthur Schoenstadt, MD
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation




Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.